The Alcoholic Hepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Alcoholic Hepatitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alcoholic Hepatitis Market.
Some of the key takeaways from the Alcoholic Hepatitis Pipeline Report:
Companies across the globe are diligently working toward developing novel Alcoholic Hepatitis treatment therapies with a considerable amount of success over the years.
Alcoholic Hepatitis companies working in the treatment market are ImmuneMed, NEXEL, Surrozen, Seal Rock Therapeutics, Intercept Pharmaceuticals, Aldeyra Therapeutics, Novartis, and others, are developing therapies for the Alcoholic Hepatitis treatment
Emerging Alcoholic Hepatitis therapies in the different phases of clinical trials are- Burfiralimab, NP-011, SZN 043, SRT-015, INT 787, ADX 629, Canakinumab, and others are expected to have a significant impact on the Alcoholic Hepatitis market in the coming years.
In November 2022, The development of Intercept Pharmaceuticals’ next-generation FXR agonist, INT-787, will concentrate on treating severe alcohol-associated hepatitis (sAH). At The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., preliminary data from Intercept’s Phase I trial of INT-787 in healthy subjects were presented. These data supported INT-787’s favourable safety and tolerability profile in healthy male and female adults.
Alcoholic Hepatitis Overview
Alcoholic liver disease has an acute form called alcoholic hepatitis. Clinically, liver failure with jaundice, coagulopathy, and encephalopathy are common clinical manifestations of the hepatic inflammation brought on by excessive alcohol use. Multiorgan failure with significant mortality can also develop.
Get a Free Sample PDF Report to know more about Alcoholic Hepatitis Pipeline Therapeutic Assessment-
Emerging Alcoholic Hepatitis Drugs Under Different Phases of Clinical Development Include:
SZN 043: Surrozen
SRT-015: Seal Rock Therapeutics
INT 787: Intercept Pharmaceuticals
ADX 629: Aldeyra Therapeutics
Canakinumab: Novartis Pharmaceuticals
Alcoholic Hepatitis Route of Administration
Alcoholic Hepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Alcoholic Hepatitis Molecule Type
Alcoholic Hepatitis Products have been categorized under various Molecule types, such as
Alcoholic Hepatitis Pipeline Therapeutics Assessment
Alcoholic Hepatitis Assessment by Product Type
Alcoholic Hepatitis By Stage and Product Type
Alcoholic Hepatitis Assessment by Route of Administration
Alcoholic Hepatitis By Stage and Route of Administration
Alcoholic Hepatitis Assessment by Molecule Type
Alcoholic Hepatitis by Stage and Molecule Type
DelveInsight’s Alcoholic Hepatitis Report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Alcoholic Hepatitis product details are provided in the report. Download the Alcoholic Hepatitis pipeline report to learn more about the emerging Alcoholic Hepatitis therapies
Some of the key companies in the Alcoholic Hepatitis Therapeutics Market include:
Key companies developing therapies for Alcoholic Hepatitis are – Gilead Sciences, Inc., Sanofi, Generon Pharmaceutical Technology (Shanghai) Co., Ltd., Immuron Ltd., Intercept Pharmaceuticals, Inc., and others.
Alcoholic Hepatitis Pipeline Analysis:
The Alcoholic Hepatitis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Alcoholic Hepatitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alcoholic Hepatitis Treatment.
Alcoholic Hepatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Alcoholic Hepatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alcoholic Hepatitis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Alcoholic Hepatitis drugs and therapies
Alcoholic Hepatitis Pipeline Market Drivers
Increase in prevalence of alcohol related diseases, development of new strategies and viable treatment options for alcoholic hepatitis management are some of the important factors that are fueling the Alcoholic Hepatitis Market.
Alcoholic Hepatitis Pipeline Market Barriers
However, lack of therapies to treat severe alcoholic hepatitis, complications associated with the disease and other factors are creating obstacles in the Alcoholic Hepatitis Market growth.
Scope of Alcoholic Hepatitis Pipeline Drug Insight
Key Alcoholic Hepatitis Companies: ImmuneMed, NEXEL, Surrozen, Seal Rock Therapeutics, Intercept Pharmaceuticals, Aldeyra Therapeutics, Novartis, and others
Key Alcoholic Hepatitis Therapies: Burfiralimab, NP-011, SZN 043, SRT-015, INT 787, ADX 629, Canakinumab, and others
Alcoholic Hepatitis Therapeutic Assessment: Alcoholic Hepatitis current marketed and Alcoholic Hepatitis emerging therapies
Alcoholic Hepatitis Market Dynamics: Alcoholic Hepatitis market drivers and Alcoholic Hepatitis market barriers
Request for Sample PDF Report for Alcoholic Hepatitis Pipeline Assessment and clinical trials
Table of Contents
1. Alcoholic Hepatitis Report Introduction
2. Alcoholic Hepatitis Executive Summary
3. Alcoholic Hepatitis Overview
4. Alcoholic Hepatitis- Analytical Perspective In-depth Commercial Assessment
5. Alcoholic Hepatitis Pipeline Therapeutics
6. Alcoholic Hepatitis Late Stage Products (Phase II/III)
7. Alcoholic Hepatitis Mid Stage Products (Phase II)
8. Alcoholic Hepatitis Early Stage Products (Phase I)
9. Alcoholic Hepatitis Preclinical Stage Products
10. Alcoholic Hepatitis Therapeutics Assessment
11. Alcoholic Hepatitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Alcoholic Hepatitis Key Companies
14. Alcoholic Hepatitis Key Products
15. Alcoholic Hepatitis Unmet Needs
16 . Alcoholic Hepatitis Market Drivers and Barriers
17. Alcoholic Hepatitis Future Perspectives and Conclusion
18. Alcoholic Hepatitis Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States